Tag Archives: Kadcyla

December, 2018

6 December
Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla® (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50 percent …
Share

15 October
Genentech’s Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla® (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin®(trastuzumab) …
Share

23 March
ImmunoGen Licenses ADC Technology to Takeda for Development of Cancer Drugs

Oncology biotech ImmunoGen, Inc. announced that it has entered into a $440 million antibody-drug conjugate (ADC) licensing deal with Takeda Pharmaceutical Company Limited. Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets. Under the deal, ImmunoGen …
Share